BioHarvest Sciences Inc. Logo

BioHarvest Sciences Inc.

CNVCF

(2.0)
Stock Price

6,30 USD

-60.63% ROA

955.64% ROE

-5.33x PER

Market Cap.

73.034.112,00 USD

155% DER

0% Yield

-76.65% NPM

BioHarvest Sciences Inc. Stock Analysis

BioHarvest Sciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioHarvest Sciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (153.37%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-11.09x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-148%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 ROA

The stock's ROA (-88.46%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

BioHarvest Sciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioHarvest Sciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioHarvest Sciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioHarvest Sciences Inc. Revenue
Year Revenue Growth
2014 0
2015 0 0%
2016 40.000 100%
2017 325.000 87.69%
2018 449.000 27.62%
2019 218.000 -105.96%
2020 396.000 44.95%
2021 2.102.000 81.16%
2022 5.498.000 61.77%
2023 8.652.000 36.45%
2023 12.672.000 31.72%
2024 24.108.000 47.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioHarvest Sciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2014 0
2015 0 0%
2016 388.000 100%
2017 429.000 9.56%
2018 553.000 22.42%
2019 1.346.000 58.92%
2020 1.264.000 -6.49%
2021 4.129.000 69.39%
2022 2.308.000 -78.9%
2023 2.444.000 5.56%
2023 3.369.000 27.46%
2024 4.352.000 22.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioHarvest Sciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 0
2015 0 0%
2016 118.521 100%
2017 89.508 -32.41%
2018 778.000 88.5%
2019 848.000 8.25%
2020 4.573.000 81.46%
2021 1.801.000 -153.91%
2022 5.050.000 64.34%
2023 3.500.000 -44.29%
2023 5.678.000 38.36%
2024 3.912.000 -45.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioHarvest Sciences Inc. EBITDA
Year EBITDA Growth
2014 -70.658
2015 -201.015 64.85%
2016 -126.935 -58.36%
2017 -92.784 -36.81%
2018 -164.748 43.68%
2019 -1.228.000 86.58%
2020 -5.685.000 78.4%
2021 -8.149.000 30.24%
2022 -9.986.000 18.4%
2023 -1.644.000 -507.42%
2023 -9.262.000 82.25%
2024 192.000 4923.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioHarvest Sciences Inc. Gross Profit
Year Gross Profit Growth
2014 0
2015 -527 100%
2016 39.517 101.33%
2017 -168.000 123.52%
2018 -14.000 -1100%
2019 29.000 148.28%
2020 138.000 78.99%
2021 670.000 79.4%
2022 1.219.000 45.04%
2023 3.168.000 61.52%
2023 5.633.000 43.76%
2024 12.408.000 54.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioHarvest Sciences Inc. Net Profit
Year Net Profit Growth
2014 -70.658
2015 -129.897 45.6%
2016 -99.604 -30.41%
2017 -4.985 -1898.07%
2018 -163.831 96.96%
2019 -4.369.271 96.25%
2020 -6.931.810 36.97%
2021 -9.740.532 28.84%
2022 -10.790.799 9.73%
2023 -3.008.000 -258.74%
2023 -12.794.408 76.49%
2024 -2.747.432 -365.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioHarvest Sciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -16 100%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioHarvest Sciences Inc. Free Cashflow
Year Free Cashflow Growth
2014 -81.587
2015 -227.220 64.09%
2016 -163.555 -38.93%
2017 -118.670 -37.82%
2018 -185.331 35.97%
2019 -2.417.000 92.33%
2020 -4.048.000 40.29%
2021 -8.434.000 52%
2022 -10.497.000 19.65%
2023 -2.031.000 -416.84%
2023 -9.996.000 79.68%
2024 -2.666.000 -274.94%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioHarvest Sciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2014 -70.658
2015 -201.015 64.85%
2016 -129.610 -55.09%
2017 -99.804 -29.87%
2018 -163.831 39.08%
2019 -2.383.000 93.13%
2020 -3.875.000 38.5%
2021 -6.794.000 42.96%
2022 -9.241.000 26.48%
2023 -1.655.000 -458.37%
2023 -8.522.000 80.58%
2024 -958.000 -789.56%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioHarvest Sciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2014 10.928
2015 26.205 58.3%
2016 33.945 22.8%
2017 18.867 -79.93%
2018 21.499 12.25%
2019 34.000 36.77%
2020 173.000 80.35%
2021 1.640.000 89.45%
2022 1.256.000 -30.57%
2023 376.000 -234.04%
2023 1.474.000 74.49%
2024 1.708.000 13.7%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioHarvest Sciences Inc. Equity
Year Equity Growth
2014 50.031
2015 20.932 -139.02%
2016 20.211 -3.57%
2017 -81.209 124.89%
2018 3.988.484 102.04%
2019 -23.406.000 117.04%
2020 -2.295.000 -919.87%
2021 2.855.000 180.39%
2022 -5.929.000 148.15%
2023 -14.853.000 60.08%
2023 -5.164.000 -187.63%
2024 6.702.000 177.05%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioHarvest Sciences Inc. Assets
Year Assets Growth
2014 58.560
2015 83.874 30.18%
2016 91.658 8.49%
2017 83.986 -9.13%
2018 388.111 78.36%
2019 2.022.000 80.81%
2020 5.304.000 61.88%
2021 10.208.000 48.04%
2022 9.393.000 -8.68%
2023 15.002.000 37.39%
2023 8.458.000 -77.37%
2024 27.014.000 68.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioHarvest Sciences Inc. Liabilities
Year Liabilities Growth
2014 8.529
2015 62.941 86.45%
2016 71.446 11.9%
2017 165.195 56.75%
2018 35.627 -363.68%
2019 28.992.000 99.88%
2020 7.599.000 -281.52%
2021 7.353.000 -3.35%
2022 15.322.000 52.01%
2023 29.855.000 48.68%
2023 13.622.000 -119.17%
2024 20.312.000 32.94%

BioHarvest Sciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.17
Net Income per Share
-1
Price to Earning Ratio
-5.33x
Price To Sales Ratio
3.83x
POCF Ratio
-13.42
PFCF Ratio
-7.97
Price to Book Ratio
13.03
EV to Sales
4.1
EV Over EBITDA
-9.26
EV to Operating CashFlow
-12.03
EV to FreeCashFlow
-8.54
Earnings Yield
-0.19
FreeCashFlow Yield
-0.13
Market Cap
0,07 Bil.
Enterprise Value
0,08 Bil.
Graham Number
3.04
Graham NetNet
-0.78

Income Statement Metrics

Net Income per Share
-1
Income Quality
0.4
ROE
3.44
Return On Assets
-0.67
Return On Capital Employed
-0.49
Net Income per EBT
1
EBT Per Ebit
2.19
Ebit per Revenue
-0.35
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.28
Research & Developement to Revenue
0.21
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.54
Operating Profit Margin
-0.35
Pretax Profit Margin
-0.77
Net Profit Margin
-0.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.4
Free CashFlow per Share
-0.56
Capex to Operating CashFlow
-0.41
Capex to Revenue
0.14
Capex to Depreciation
2.69
Return on Invested Capital
-0.4
Return on Tangible Assets
-0.61
Days Sales Outstanding
29.08
Days Payables Outstanding
155.81
Days of Inventory on Hand
98.97
Receivables Turnover
12.55
Payables Turnover
2.34
Inventory Turnover
3.69
Capex per Share
0.16

Balance Sheet

Cash per Share
0,32
Book Value per Share
0,41
Tangible Book Value per Share
0.41
Shareholders Equity per Share
0.41
Interest Debt per Share
1.08
Debt to Equity
1.55
Debt to Assets
0.38
Net Debt to EBITDA
-0.62
Current Ratio
1.04
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
17675000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2620620.5
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioHarvest Sciences Inc. Dividends
Year Dividends Growth

BioHarvest Sciences Inc. Profile

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.

CEO
Mr. Ilan Sobel
Employee
0
Address
1140-625 Howe Street
Vancouver, V6C 2T6

BioHarvest Sciences Inc. Executives & BODs

BioHarvest Sciences Inc. Executives & BODs
# Name Age
1 Mr. Matthew Joseph Zrebiec
Vice President of Business Development
70
2 Ms. Bar Dichter
Chief Financial Officer
70
3 Dr. Ilana Belzer Ph.D.
Chief Operating Officer
70
4 Dr. Zaki Rakib Ph.D.
Co-Founder, Executive Chairman & President
70
5 Dr. Yochi Hagay Ph.D.
Co-Founder, Chief Technology Officer & Member of Scientific Advisory Board
70
6 Mr. David K. Ryan
Vice President of Investor Relations & Secretary
70
7 Dr. Brian S. Cornblatt
Chief Medical Officer & Member of Scientific Advisory Board
70
8 Mr. Ilan Sobel
Chief Executive Officer
70

BioHarvest Sciences Inc. Competitors